Structural basis of ligand recognition and design of antihistamines targeting histamine H<sub>4</sub> receptor.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38509098.
- Also identified by DOI 10.1038/s41467-024-46840-5 and PMC identifier 10954740.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The histamine H<sub>4</sub> receptor (H<sub>4</sub>R) plays key role in immune cell function and is a highly valued target for treating allergic and inflammatory diseases. However, structural information of H<sub>4</sub>R remains elusive. Here, we report four cryo-EM structures of H<sub>4</sub>R/G<sub>i</sub> complexes, with either histamine or synthetic agonists clobenpropit, VUF6884 and clozapine bound. Combined with mutagenesis, ligand binding and functional assays, the structural data reveal a distinct ligand binding mode where D94<sup>3.32</sup> and a π-π network determine the orientation of the positively charged group of ligands, while E182<sup>5.46</sup>, located at the opposite end of the ligand binding pocket, plays a key role in regulating receptor activity. The structural insight into H<sub>4</sub>R ligand binding allows us to identify mutants at E182<sup>5.46</sup> for which the agonist clobenpropit acts as an inverse agonist and to correctly predict inverse agonism of a closely related analog with nanomolar potency. Together with the findings regarding receptor activation and G<sub>i</sub> engagement, we establish a framework for understanding H<sub>4</sub>R signaling and provide a rational basis for designing novel antihistamines targeting H<sub>4</sub>R.
Medical subject headings
- Histamine
- Drug Inverse Agonism
- Imidazoles
- Thiourea